Literature DB >> 19913351

Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.

Martin C Schumacher1, Sten Holmäng, Thomas Davidsson, Bengt Friedrich, Jörgen Pedersen, N Peter Wiklund.   

Abstract

BACKGROUND: Fluorescent light (FL)-guided cystoscopy induced by 5-aminolevulinic acid (5-ALA) has been reported to detect more tumours compared with standard white-light (WL) cystoscopy. Most reports are from single centres with relatively few patients.
OBJECTIVE: To evaluate whether 5-ALA-induced FL and WL cystoscopy at transurethral resection (TUR) is superior compared with standard procedures under WL only with respect to tumour recurrence and progression in patients with non-muscle-invasive bladder cancer. DESIGN, SETTING, AND PARTICIPANTS: This randomised, multicentre, observer- and pathologist-blinded, prospective phase 3 clinical trial enrolled 300 patients, and of those patients, 153 were randomised to FL cystoscopy and 147 were randomised to standard WL cystoscopy. INTERVENTION: All patients were first inspected under WL and all lesions were recorded. Patients randomised to FL underwent a second inspection. TUR was carried out in both groups. MEASUREMENTS: Control cystoscopy under WL was performed in all patients every 3 mo during the first year after randomisation and biannually thereafter. RESULTS AND LIMITATIONS: At the first TUR, the mean number of resection specimens per patient was 2.5 (FL: 2.5; WL: 2.4; p=0.37) and the resulting mean number of resected tumours was 1.7 with FL and 1.8 with WL (p=0.85). More patients were diagnosed with carcinoma in situ (CIS) in the WL group (13%) than in the FL group (4.2%). Within-patient comparison of FL patients only showed that FL detected more lesions than WL. Tumour lesions solely detected by FL cystoscopy that would not otherwise be detected by WL cystoscopy included 52% dysplasia, 33% CIS, 18% papillary neoplasms, 13% pT1, and 7% pTa. Outcome at 12 mo did not show any difference between groups with regard to recurrence-free and progression-free survival rates.
CONCLUSIONS: In this prospective, randomised, multi-institutional study, we found no clinical advantage of FL cystoscopy compared with WL cystoscopy and TUR. Copyright 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19913351     DOI: 10.1016/j.eururo.2009.10.030

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  37 in total

Review 1.  [Diagnostic procedure for bladder cancer. Standards and current developments].

Authors:  A Karl; S Tritschler; D Zaak; D Tilki; C Stief; M Burger
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

Review 2.  [Urothelial carcinoma].

Authors:  H Rübben; F Vom Dorp
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

Review 3.  [Photodynamic diagnostics of bladder carcinoma].

Authors:  F Vom Dorp; S Tschirdewahn; T Olbricht; T Szarvas; H Rübben
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

Review 4.  [Current developments in the diagnostics and therapy of bladder carcinoma].

Authors:  J Kamradt; C-H Ohlmann; M Stöckle
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

Review 5.  The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.

Authors:  Eugene J Pietzak
Journal:  Curr Urol Rep       Date:  2017-05       Impact factor: 3.092

Review 6.  [Diagnostics of nonmuscle-invasive urothelial cell carcinoma of the bladder].

Authors:  S Tschirdewahn; F Vom Dorp
Journal:  Urologe A       Date:  2015-04       Impact factor: 0.639

7.  Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.

Authors:  Alexander I Rolevich; Alexander G Zhegalik; Andrey A Mokhort; Alexander A Minich; Vladimir Yu Vasilevich; Sergey L Polyakov; Sergey A Krasny; Oleg G Sukonko
Journal:  World J Urol       Date:  2016-09-07       Impact factor: 4.226

8.  [Diagnostic work-up and treatment of bladder cancer: current developments].

Authors:  C-H Ohlmann; M Stöckle
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

9.  [Narrow band imaging-assisted cystoscopy in bladder tumor follow-up: Can more tumors be identified?].

Authors:  L Hirner; E Stagge; H Rübben; M Schenck; A Eisenhardt
Journal:  Urologe A       Date:  2016-03       Impact factor: 0.639

Review 10.  Approaching the optimal transurethral resection of a bladder tumor.

Authors:  Michael Jurewicz; Mark S Soloway
Journal:  Turk J Urol       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.